Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Coiled Thera (COIL) Share Price

Price 7.50p on 28-09-2026 at 18:15:12
Change 0.00p 0%
Buy 8.00p
Sell 7.00p
Last Trade: Sell 250,000.00 at 6.933p
Day's Volume: 1,021,730
Last Close: 7.50p
Open: 7.50p
ISIN: GB00BSHRN331
Day's Range 7.50p - 7.50p
52wk Range: 6.75p - 12.00p
Market Capitalisation: £32.01m
VWAP: 7.291923p
Shares in Issue: 426.79m

Coiled Thera (COIL) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Sell* 250,000 6.933p Negotiated Trade
16:40:03 - 28-Sep-26
Unknown* 4,765 7.50p Uncrossing Trade
16:35:16 - 28-Sep-26
Sell* 50,000 7.00p Negotiated Trade
16:22:31 - 28-Sep-26
Sell* 4,377 7.25p Ordinary
13:09:32 - 28-Sep-26
Sell* 4,000 7.00p Ordinary
12:50:45 - 28-Sep-26
Sell* 12,470 7.25p Ordinary
11:57:00 - 28-Sep-26
Sell* 81,890 7.25p Ordinary
10:53:32 - 28-Sep-26
Sell* 81,890 7.12p Negotiated Trade
10:36:30 - 28-Sep-26
Buy* 68 8.00p SI Trade
10:35:44 - 28-Sep-26
Buy* 12 8.00p SI Trade
10:35:44 - 28-Sep-26
See more Coiled Thera trades

Coiled Thera (COIL) Share Price History

Time period:
to
Date Open High Low Close Volume
28th Sep 2026 (Mon) 7.50 7.50 7.50 7.50 1,021,730
25th Sep 2026 (Fri) 7.75 8.00 7.50 7.50 244,348
24th Sep 2026 (Thu) 7.75 7.75 7.75 7.75 30,000
23rd Sep 2026 (Wed) 8.00 8.00 7.75 7.75 171,352
22nd Sep 2026 (Tue) 8.00 8.50 8.00 8.00 303,280
21st Sep 2026 (Mon) 8.00 8.50 8.00 8.00 37,529
18th Sep 2026 (Fri) 8.00 8.00 8.00 8.00 52,764
17th Sep 2026 (Thu) 8.00 8.00 8.00 8.00 266,348
16th Sep 2026 (Wed) 8.00 8.00 8.00 8.00 104,751
15th Sep 2026 (Tue) 8.00 8.50 7.50 8.50 33,323
14th Sep 2026 (Mon) 8.50 7.85 7.85 7.85 663,164
11th Sep 2026 (Fri) 8.50 8.50 8.50 8.50 0
10th Sep 2026 (Thu) 8.50 8.50 7.85 8.50 10,041
9th Sep 2026 (Wed) 8.50 8.50 8.50 8.50 5,370
8th Sep 2026 (Tue) 8.50 8.50 8.50 8.50 6,275
7th Sep 2026 (Mon) 8.50 8.50 8.50 8.50 53,196
4th Sep 2026 (Fri) 8.75 9.00 8.50 8.50 220,334
3rd Sep 2026 (Thu) 8.75 9.00 9.00 9.00 119,793
2nd Sep 2026 (Wed) 8.75 8.75 8.75 8.75 0
1st Sep 2026 (Tue) 9.00 9.00 8.75 8.75 20,615
31st Aug 2026 (Mon) 8.75 8.75 8.75 8.75 0
See more Coiled Thera price history

Coiled Thera (COIL) Regulatory News

Date Source Headline
28th Sep 2026 10:33 am RNS Director/PDMR Shareholding
28th Sep 2026 7:00 am RNS Interim Results to 30 June 2026
21st Sep 2026 7:00 am RNS Successful Enrolment Completed Across Two Cohorts
1st Sep 2026 7:00 am RNS Appointment of Joint Corporate Broker
10th Aug 2026 11:57 am RNS Change of Registered Office
3rd Aug 2026 7:00 am RNS First Patient Dosed with new Formulation of AO-252
7th Jul 2026 7:00 am RNS Coiled Advances Next-Generation AO-252 Formulation
24th Jun 2026 12:30 pm RNS-R Company Presentation
24th Jun 2026 11:18 am RNS Result of AGM
24th Jun 2026 7:00 am RNS Appointment of Independent Non-Executive Director
See more Coiled Thera regulatory news

Coiled Thera (COIL) Share News

EARNINGS: Likewise expects FY sales beat; lower costs help Blackbird

28th Sep 2026 15:50

(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Monday and not separately reported by Alliance News: Read More

IN BRIEF: Coiled Therapeutics progresses AO-252 testing enrolment

21st Sep 2026 19:14

Coiled Therapeutics PLC - London-based clinical-stage oncology company - Says it has successfully enrolled patients across two escalation cohorts for the clinical development of its lipid-based formulation of brain-penetrant small-molecule TACC3 inhibitor AO-252. One cohort will be given a twice-daily 120 miligram dose, the other 160mg once a day. "All patients are progressing as planned through the assessment period, in accordance with the study protocol," Coiled says. Explains that the new formulation "is designed to achieve more consistent, dose-proportional absorption," in light of the 80% clinical benefit rate signal it observed in twice-daily tablet dosing. The dosages "were selected to optimise systemic drug exposure based on encouraging clinical activity observed with the original tablet formulation." Coiled says enrolment marks further progress towards its planned phase 1/2 dose-expansion cohorts in ovarian and prostate cancer. It aims to enrol up to 30 patients with the new formulation by the end of 2026, and also continues to expect initial safety and pharmacokinetic data readouts by the end of 2026. Read More

TRADING UPDATES: Cizzle Biotechnology strikes US strategic lab deal

3rd Aug 2026 20:56

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More

UK shareholder meetings calendar - next 7 days

17th Jun 2026 11:53

Read More

Coiled Therapeutics shares rise as cross trading begins in New York

19th May 2026 14:25

(Alliance News) - Coiled Therapeutics PLC on Tuesday reported its US trading launch. Read More

See more Coiled Thera news
FTSE 100 Latest
Value10,684.88
Change-10.37

Login to your account

Forgot Password?

Not Registered